🤔 Empagliflozin in acute decompensated heart failure

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (Voors, Nature Medicine 2023)

🤔 EMPA KIDNEY analysis by CKD diagnosis

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)

🤔 EMPA Kidney sub-group analysis by DM and ACR status

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)

🤔 Flozination reduces kidney stones

Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes (JAMA 2024)